TOKOS PREPARING FOR END-OF-YEAR ROLL-OUT OF ADEZA'S FETAL FIBRONECTIN TEST; ASSAY APPROVED FOR DETERMINING DELIVERY TIMING IN SYMPTOMATIC WOMEN
This article was originally published in The Gray Sheet
Executive SummaryTokos plans to begin U.S. marketing of Adeza Biomedical's fetal Fibronectin (fFN) assay in two-to-three months. On Sept. 21, FDA informed Adeza that it has approved the ELISA-based test as an aid in determining whether preterm delivery is imminent for symptomatic women between 24 and 34.6 completed weeks gestation who have intact amniotic membranes and are experiencing less than 3 cm cervical dilation.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.